U.S. stocks were mostly higher on Tuesday despite persisting uncertainty regarding the U.S.-China partial trade deal. Moreover, investors’ are waiting for Fed Chair Jerome Powell’s congressional testimony on Nov 13. Both the S&P 500 and the Nasdaq Composite ended in the green while the Dow remained flat.
The Dow Jones Industrial Average (DJI) remained flat to close at 27,691.49. The S&P 500 increased 0.2% to close at 3,091.84. Meanwhile, the Nasdaq Composite Index closed at 8,486.09, gaining 0.3%. The fear-gauge CBOE Volatility Index (VIX) decreased 0.1% to close at 12.68. A total of 6.6 billion shares were traded Monday, lower than the last 20-session average of 6.8 billion. Decliners outnumbered advancers on the NYSE by a 1.04-to-1 ratio. On Nasdaq, the ratio was nearly even.
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="How Did The Benchmarks Perform?” data-reactid=”20″>How Did The Benchmarks Perform?
The Dow remained same at previous day’s level, marking the blue-chip index’sfirst completely flat close since Apr, 24, 2014. The S&P 500 closed in the green. The Real Estate Select Sector SPDR (XLRE) lost 0.7% while the Health Care Select Sector SPDR (XLV) gained 0.6%. The tech-laden Nasdaq Composite finished in the positive territory due to performance of large-cap tech stocks.
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Both the S&P 500 and the Nasdaq Composite benefitted from Facebook Inc. FB that rallied 2.6% r announcing a new payments tool that can be used through its applications. Facebook carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.” data-reactid=”22″>Both the S&P 500 and the Nasdaq Composite benefitted from Facebook Inc. FB that rallied 2.6% r announcing a new payments tool that can be used through its applications. Facebook carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Uncertainty Regarding Partial Trade Deal” data-reactid=”23″>Uncertainty Regarding Partial Trade Deal
On Nov 12, President Donald Trump delivered a speech at the Economic Club of New York, where he said a U.S.-China trade deal “could happen soon,” and added that a phase one agreement is “close.” The partial trade deal was scheduled to be signed by both sides in mid-November. However, it has already been postponed to next month.
At the same time, he threatened more tariff hikes on Chinese imports if the trade negotiation fails to produce an interim agreement. Trump has categorically mentioned that he would only accept the interim trade deal if the agreement worked to the advantage of U.S. workers and businesses.
In a strong statement, he said “since China’s entrance into the World Trade Organization in 2001, no one has manipulated better or taken advantage of the United States more.” “I will not say the word ‘cheated,’ but nobody’s cheated better than China, I will say that.”
On Nov 8, President Donald Trump told reports that he hasn’t agreed so far to roll back the existing tariffs in phases that his administration imposed on Chinese goods over the past one and half years. Moreover, senior U.S. Trade Advisor Peter Navarro said that no formal agreement has taken place between the United States and China to remove tariffs on each other goods.
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>” data-reactid=”28″>Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Facebook, Inc. (FB) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research” data-reactid=”29″>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Facebook, Inc. (FB) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Add Comment